GTCR in Talks for Private Debt to Fund Bid for Drugmaker Zentiva

Private equity firm GTCR is in talks with direct lenders including KKR & Co. to drum up financing to support a bid to acquire generic drugmaker Zentiva, according to people with knowledge of the matter.

Talks are ongoing and there’s no guarantee a deal will materialize, said the people, who asked not to be identified discussing private information.

Representatives for KKR and Advent International, the buyout firm that owns Zentiva, declined to comment. GTCR and Zentiva didn’t immediately respond to requests for comment.

GTCR, TPG Inc. and Indian drugmaker Aurobindo Pharma Ltd. were among those considering bids for ...